A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diabetes

Trial Identifier: EFC18241
Sponsor: Sanofi
Start Date: August 2025
Primary Completion Date: June 2028
Study Completion Date: December 2028
Condition: Diabetes: Type 1

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
UNITED KINGDOM, Scotland Dundee, Scotland, UNITED KINGDOM, DD1 9SY
UNITED STATES, Arizona SCOTTSDALE, Arizona, UNITED STATES, 85260
UNITED STATES, California HUNTINGTON BEACH, California, UNITED STATES, 92647
UNITED STATES, Georgia Atlanta, Georgia, UNITED STATES, 30318
UNITED STATES, Georgia Columbus, Georgia, UNITED STATES, 31904
UNITED STATES, Georgia Stockbridge, Georgia, UNITED STATES, 30281
UNITED STATES, Idaho Idaho Falls, Idaho, UNITED STATES, 83404
UNITED STATES, Minnesota Rochester, Minnesota, UNITED STATES, 55905
UNITED STATES, North Carolina Asheville, North Carolina, UNITED STATES, 28803
UNITED STATES, Washington Seattle, Washington, UNITED STATES, 98101-2795